WASHINGTON — The tax overhaul that Republicans hope to send to President Trump’s desk next week is expected to lighten the tax burden on the pharmaceutical industry and provide a number of other benefits that could help drug makers boost their bottom lines.
The final version of the bill, released late Friday, retains a key tax credit aimed at incentivizing research into rare disease treatments — an improvement over an early draft that repealed it for the industry. The package will also lower the tax rate companies have to pay on earnings they stockpiled overseas, though the final rate is higher than in earlier drafts.
Drugmakers, like many large corporations, will also benefit from the flat 21 percent corporate tax rate and the elimination of the corporate alternative minimum tax, two key pillars of the deal that was announced earlier this week.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect